With our new-found understanding of cancer biology comes the opportunity to explain a disease that for centuries has confounded doctors and engendered stigma and superstition. Siddhartha Mukherjee took that opportunity and turned it into a [more]
With two novel immunotherapies approved and many more in the pipeline, is it time to announce that a new treatment modality has emerged? A class of therapy that has long held promise for treating cancer [more]
Why are cancer patients being given medically futile treatment in the last weeks of their life? We hear this question raised time and again at international meetings and in journal articles, provoking polarised views and [more]
It was her own fault that she lost her chance to be cured. Or was it? This article, which was first published in the German weekly news magazine Der Spiegel, and won its author a [more]
When your patient is pregnant, uncertainty about the impact different therapies may have on the child makes it hard to discuss treatment options. A study of children exposed to cancer treatments before birth is now [more]
Knowing what needs to be done is one thing. Making it happen is quite another. Well-informed media stories that highlight shortcomings and failings can help focus minds on the need for urgent action. The media [more]
Recent evolution of prostate cancer treatment reflects technological arms races driven by economic incentives rather than high-quality evidence as exemplified by proton-beam radiation, recently found markedly inferior to far less expensive alternatives. Another study [more]
Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years with acute myeloid leukaemia (AML). More-recent randomised trials demonstrate that [more]
Selected reports edited by Janet Fricker Preoperative chemoradio-therapy improves survival in oesophageal cancer => New England Journal of Medicine Preoperative chemoradiotherapy improves survival among patients with potentially curable oesophageal or oesophagogastric-junction cancers, a phase III [more]
Ruth Conroy is a specialist registrar in clinical oncology at the Christie Hospital in Manchester, UK. She came first out of a class of 62 young oncologists from 28 countries in the learning assessment test [more]